Tirzepatide emerges a groundbreaking therapeutic agent for individuals struggling type 2 diabetes. As a dual agonist, it targets both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic https://dawudxesk701382.csublogs.com/48333307/tirzepatide-a-novel-glp-1-and-gip-receptor-agonist